Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock and Warrants
-
Shares outstanding
-
55,095,630
-
Total 13F shares
-
8,284,557
-
Share change
-
-6,056,273
-
Total reported value
-
$8,781,263
-
Price per share
-
$1.06
-
Number of holders
-
36
-
Value change
-
-$8,600,258
-
Number of buys
-
17
-
Number of sells
-
14
Institutional Holders of AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX) as of Q2 2025
As of 30 Jun 2025,
AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX) was held by
36 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
8,284,557 shares.
The largest 10 holders included
Almitas Capital LLC, VANGUARD GROUP INC, Pfizer Inc, Peapod Lane Capital LLC, Stonepine Capital Management, LLC, LANDSCAPE CAPITAL MANAGEMENT, L.L.C., BANK OF NOVA SCOTIA, BANK OF MONTREAL /CAN/, RENAISSANCE TECHNOLOGIES LLC, and BANK OF AMERICA CORP /DE/.
This page lists
36
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.